Different Anticoagulant and Immunological Properties of Anti-Prothrombin Antibodies in Patients with Antiphospholipid Antibodies

Summary

Lupus anticoagulant (LA) antibodies are acquired inhibitors of coagulation belonging – together with anticardiolipin (aCL) antibodies – to the family of antiphospholipid antibodies. Since LA antibodies affect coagulation reactions via recognition of the complex of lipid-bound prothrombin, they may be better named anti-prothrombin antibodies. We studied their immunological properties in the plasma of 59 patients with antiphospholipid antibodies by means of specific ELISA systems that allowed the characterization of the interaction of these antibodies with human prothrombin and anionic phospholipids. The mode of presentation of prothrombin was found to greatly influence the reactivity of anti-prothrombin antibodies. In fact, when plain polystyrene plates were used to immobilize prothrombin, virtually no binding was observed. Conversely, when prothrombin was coated on high-activated PVC ELISA plates, 34 samples (58%) contained antibodies that recognize human prothrombin in solid phase. In particular, IgG antibodies were found in 21 plasmas and IgM in 22; both IgG and IgM isotypes were present in 9 of these cases. A higher prevalence was observed in the ELISA for the detection of the antibodies directed at the calcium- mediated complex of phosphatidylserine (PS)-bound prothrombin: 53 samples (90%), preadsorbed with cardiolipin liposomes to remove aCL antibodies, showed the presence of IgG and/or IgM anti-prothrombin antibodies. When the results were analyzed according to the immunoglobulin isotypes, 44 (75%) and 39 (66%) samples were found to contain IgG and IgM anti-prothrombin antibodies, respectively. Both IgG and IgM were present in the plasma of 30 patients. Only half of these samples reacted also with PVC-bound prothrombin. Apparently, the higher rate of positivity of the ELISA for the detection of antibodies to the complex of PS-bound prothrombin was not due to differences in the amount of antigen available in the 2 systems, as judged by binding experiments performed with a rabbit polyclonal anti-human prothrombin antiserum.

Finally, the anticoagulant properties of 14 total IgG preparations (12 of them contained anti-prothrombin antibodies positive in both ELISA systems, whereas the other 2 cases reacted either with PVC-bound prothrombin only or with PS-bound prothrombin only) were evaluated by diluted Russell’s Viper Venom Time and by diluted activated Partial Thromboplastin Time. To rule out the β₂-glycoprotein I (β₂-GPI)-de- pendent anticoagulant effect of the aCL antibodies contained in the preparations, the coagulation tests were performed in (β₂-GPI deficient plasma. Six preparations failed to show anticoagulant activity in both assay systems, suggesting that 2 types of IgG anti-prothrombin antibodies exist, that differ with respect to their anticoagulant properties. These findings suggest that anti-prothrombin antibodies resemble aCL antibodies with respect to the behaviour in “in vitro” coagulation reactions and underline the wide heterogeneity of antiphospholipid antibodies.

• References

• 1 Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177-178
• 2 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation:β₂-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124
• 3 Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda Vriesman PJC, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547
• 4 Arvieux J, Roussel B, Jacob MC, Colomb MG. Measurement of antiphospholipid antibodies by ELISA using β₂-glycoprotein I as an antigen. J Immunol Meth 1991; 143: 223-229
• 5 Matsuura E, Igarashi V, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize β₂-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457-462
• 6 Galli M, Comfurius P, Barbui T, Zwaal RFA, Bevers EM. Anticoagulant activity of p₂-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 1992; 68: 297-300
• 7 Galli M, Bevers EM, Comfurius P, Barbui T, Zwaal RFA. Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles. Br J Haematol 1993; 83: 466-471
• 8 Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG’s (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-632
• 9 Bajaj SP, Rapaport SI, Fierer DS, Herbst KD, Schwartz DB. A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 1983; 61: 684-692
• 10 Edson JR, Vogt JM, Hasegawa DK. Abnormal prothrombin crossed-immu- noelecrophoresis in patients with lupus inhibitors. Blood 1984; 64: 807-816
• 11 Permpikul P, Rao LVM, Rapaport SI. Functional and binding studies of the roles of prothrombin and β₂-glycoprotein I in the expression of lupus anticoagulant activity. Blood 1994; 83: 2878-2892
• 12 Rao LVM, Hoang AD, Rapaport SI. Differences in the interactions of lupus anticoagulant IgG with human prothrombin and bovine prothrombin. Thromb Haemost 1995; 73: 668-674
• 13 Arvieux J, Darnige L, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost 1995; 74: 1120-1125
• 14 Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed at a combination of phospholipids with prothrombin, protein C or protein S:an explanation for their pathogenetic mechanism?. Blood 1993; 81: 2618-2625
• 15 Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants:an update. Thromb Haemost 1995; 74: 1185-1190
• 16 Loizou S, McCrea JD, Rudge AC, Reynolds R, Boyle CC, Harris EN. Measurement of anticardiolipin antibodies by enzyme-linked immunosorbent assay:standardization and quantitation of results. Clin Exp Immunol 1985; 62: 738-744
• 17 Harris EN, Gharavi AE, Hughes GRV. The anti-cardiolipin assay. In: Harris EN, Exner T, Hughes GRV, Asherson R. (eds.) Phospholipid-binding antibodies CRC Press; Boca Raton: p 1991 pp 175-187
• 18 Galli M, Daldossi M, Cortelazzo S, Barbui T. Increased levels of β₂-glyco- protein I (aca-Cofactor) in patients with lupus anticoagulant. Thromb Haemost 1992; 67: 386 (letter)
• 19 Sedmak JJ, Grossberg SE. A rapid, sensitive and versatile assay for protein using Coomassie brilliant blue G250. Annal Biochem 1977; 79: 544-552
• 20 Galli M, Finazzi G, Bevers EM, Barbui T. Kaolin Clotting Time and dilute Russell’s Viper Venom Time distinguish between prothrombin- and β₂- glycoprotein I-dependent antiphospholipid antibodies. Blood 1995; 86: 617-622
• 21 Pengo V, Biasiolo A, Fior MG. Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when β₂-glycoprotein I is bound to a suitable surface. Thromb Haemost 1995; 73: 29-34
• 22 Roubey RAS, Eisenberg RA, Harper MF, Winfield JB. “Anticardiolipin”autoantibodies recognize β₂-glycoprotein I in the absence of phospholipid. Importance of antigen density and bivalent binding. J Immunol 1995; 154: 954-960
• 23 Wu JR, Lenz BR. Phospholipid-specific conformational changes in human prothrombin upon binding to procoagulant acid lipid membranes. Thromb Haemost 1994; 71: 596-604
• 24 Fleck RA, Rapaport SI, Mohan RL. Anti-prothrombin antibodies and the lupus anticoagulant. Blood 1988; 72: 512-519